



- (c) formulating a compound with the same structure as that selected in step (b), or a pharmaceutically acceptable salt thereof, with a pharmaceutically acceptable carrier or excipient.

5 8. The process of claim 7, additionally comprising the following steps:

- (d) packaging the formulation of step (c);
- (e) making the package of step (d) available to a patient suffering from hypertension.

10 9. A process for preparing a medicament for the treatment of hypertension, comprising the steps of (a) testing compounds in a ligand binding assay against Kiss-1 receptor or testing compounds in an assay, measuring the inhibition of the agonist-stimulated second messenger response of Kiss-1
15 receptors, (b) identifying one or more compounds capable of antagonising the Kiss-1 receptor with an IC_{50} of less than 100nM; and (c) preparing a quantity of those one or more identified compounds.

10. A method of preparing a composition for treating hypertension which comprises:

- 20 (a) identifying a compound which specifically binds to the Kiss-1 receptor by a method which comprises contacting cells expressing Kiss-1 receptor or membranes prepared from such cells with a radiolabelled Kiss-1 receptor ligand in the presence or absence of a test compound, measuring the radioactivity bound to the cells or membranes, comparing the radioactivity
25 bound to the cells or membranes in the presence and absence of test compound, whereby a compound which causes a reduction in the radioactivity bound is a compound specifically binding to Kiss-1 receptor; and
- (b) admixing said compound with a carrier.

30

11. A method of preparing a composition for treating hypertension which comprises:

- (a) identifying a compound which specifically binds to and inhibits the activation of a Kiss-1 receptor by a method which comprises separately